vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

Eventbrite, Inc. is the larger business by last-quarter revenue ($73.5M vs $62.5M, roughly 1.2× TREACE MEDICAL CONCEPTS, INC.). Eventbrite, Inc. runs the higher net margin — -11.1% vs -15.0%, a 3.9% gap on every dollar of revenue. On growth, Eventbrite, Inc. posted the faster year-over-year revenue change (-3.9% vs -9.0%). TREACE MEDICAL CONCEPTS, INC. produced more free cash flow last quarter ($-10.4M vs $-60.9M). Over the past eight quarters, TREACE MEDICAL CONCEPTS, INC.'s revenue compounded faster (10.6% CAGR vs -7.7%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

EB vs TMCI — Head-to-Head

Bigger by revenue
EB
EB
1.2× larger
EB
$73.5M
$62.5M
TMCI
Growing faster (revenue YoY)
EB
EB
+5.1% gap
EB
-3.9%
-9.0%
TMCI
Higher net margin
EB
EB
3.9% more per $
EB
-11.1%
-15.0%
TMCI
More free cash flow
TMCI
TMCI
$50.4M more FCF
TMCI
$-10.4M
$-60.9M
EB
Faster 2-yr revenue CAGR
TMCI
TMCI
Annualised
TMCI
10.6%
-7.7%
EB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EB
EB
TMCI
TMCI
Revenue
$73.5M
$62.5M
Net Profit
$-8.2M
$-9.4M
Gross Margin
68.1%
80.6%
Operating Margin
-12.4%
-9.5%
Net Margin
-11.1%
-15.0%
Revenue YoY
-3.9%
-9.0%
Net Profit YoY
2.5%
-1775.0%
EPS (diluted)
$-0.08
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
TMCI
TMCI
Q4 25
$73.5M
$62.5M
Q3 25
$71.7M
$50.2M
Q2 25
$72.8M
$47.4M
Q1 25
$73.8M
$52.6M
Q4 24
$76.5M
$68.7M
Q3 24
$77.8M
$45.1M
Q2 24
$84.6M
$44.5M
Q1 24
$86.3M
$51.1M
Net Profit
EB
EB
TMCI
TMCI
Q4 25
$-8.2M
$-9.4M
Q3 25
$6.4M
$-16.3M
Q2 25
$-2.1M
$-17.4M
Q1 25
$-6.6M
$-15.9M
Q4 24
$-8.4M
$-501.0K
Q3 24
$-3.8M
$-15.4M
Q2 24
$1.1M
$-21.2M
Q1 24
$-4.5M
$-18.7M
Gross Margin
EB
EB
TMCI
TMCI
Q4 25
68.1%
80.6%
Q3 25
67.9%
79.1%
Q2 25
67.5%
79.7%
Q1 25
66.9%
79.7%
Q4 24
68.2%
80.7%
Q3 24
68.5%
80.1%
Q2 24
70.9%
80.2%
Q1 24
71.0%
80.2%
Operating Margin
EB
EB
TMCI
TMCI
Q4 25
-12.4%
-9.5%
Q3 25
-1.3%
-31.2%
Q2 25
-8.7%
-35.8%
Q1 25
-13.2%
-29.6%
Q4 24
-10.2%
-0.3%
Q3 24
-11.5%
-33.6%
Q2 24
-7.6%
-48.1%
Q1 24
-8.8%
-37.1%
Net Margin
EB
EB
TMCI
TMCI
Q4 25
-11.1%
-15.0%
Q3 25
8.9%
-32.4%
Q2 25
-2.9%
-36.7%
Q1 25
-9.0%
-30.3%
Q4 24
-11.0%
-0.7%
Q3 24
-4.8%
-34.1%
Q2 24
1.3%
-47.7%
Q1 24
-5.2%
-36.5%
EPS (diluted)
EB
EB
TMCI
TMCI
Q4 25
$-0.08
$-0.14
Q3 25
$0.06
$-0.26
Q2 25
$-0.02
$-0.28
Q1 25
$-0.07
$-0.25
Q4 24
$-0.09
$-0.01
Q3 24
$-0.04
$-0.25
Q2 24
$0.01
$-0.34
Q1 24
$-0.05
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$299.9M
$48.4M
Total DebtLower is stronger
$144.4M
$55.6M
Stockholders' EquityBook value
$179.1M
$87.3M
Total Assets
$647.2M
$190.6M
Debt / EquityLower = less leverage
0.81×
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
TMCI
TMCI
Q4 25
$299.9M
$48.4M
Q3 25
$57.4M
Q2 25
$69.3M
Q1 25
$76.1M
Q4 24
$441.5M
$75.7M
Q3 24
$24.7M
$82.8M
Q2 24
$56.7M
$95.0M
Q1 24
$113.7M
$110.0M
Total Debt
EB
EB
TMCI
TMCI
Q4 25
$144.4M
$55.6M
Q3 25
$174.9M
$53.5M
Q2 25
$241.3M
$53.5M
Q1 25
$241.0M
$53.4M
Q4 24
$240.7M
$53.3M
Q3 24
$240.4M
$53.2M
Q2 24
$358.7M
$53.2M
Q1 24
$358.2M
$53.1M
Stockholders' Equity
EB
EB
TMCI
TMCI
Q4 25
$179.1M
$87.3M
Q3 25
$189.1M
$89.2M
Q2 25
$177.2M
$97.6M
Q1 25
$173.3M
$105.3M
Q4 24
$170.2M
$112.9M
Q3 24
$179.8M
$104.9M
Q2 24
$176.2M
$112.1M
Q1 24
$184.1M
$126.4M
Total Assets
EB
EB
TMCI
TMCI
Q4 25
$647.2M
$190.6M
Q3 25
$744.6M
$196.6M
Q2 25
$784.1M
$206.4M
Q1 25
$812.3M
$205.8M
Q4 24
$752.3M
$217.1M
Q3 24
$817.4M
$212.9M
Q2 24
$894.5M
$226.1M
Q1 24
$952.2M
$242.7M
Debt / Equity
EB
EB
TMCI
TMCI
Q4 25
0.81×
0.64×
Q3 25
0.92×
0.60×
Q2 25
1.36×
0.55×
Q1 25
1.39×
0.51×
Q4 24
1.41×
0.47×
Q3 24
1.34×
0.51×
Q2 24
2.04×
0.47×
Q1 24
1.95×
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
TMCI
TMCI
Operating Cash FlowLast quarter
$-60.8M
$-8.0M
Free Cash FlowOCF − Capex
$-60.9M
$-10.4M
FCF MarginFCF / Revenue
-82.8%
-16.7%
Capex IntensityCapex / Revenue
0.0%
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.6M
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
TMCI
TMCI
Q4 25
$-60.8M
$-8.0M
Q3 25
$36.7M
$-9.1M
Q2 25
$-17.5M
$-3.0M
Q1 25
$59.4M
$4.2M
Q4 24
$-45.3M
$-4.2M
Q3 24
$44.6M
$-11.8M
Q2 24
$-32.3M
$-13.9M
Q1 24
$68.6M
$-7.2M
Free Cash Flow
EB
EB
TMCI
TMCI
Q4 25
$-60.9M
$-10.4M
Q3 25
$36.6M
$-11.9M
Q2 25
$-17.5M
$-7.8M
Q1 25
$59.4M
$655.0K
Q4 24
$-45.3M
$-7.3M
Q3 24
$44.4M
$-14.7M
Q2 24
$-32.4M
$-15.6M
Q1 24
$68.2M
$-11.1M
FCF Margin
EB
EB
TMCI
TMCI
Q4 25
-82.8%
-16.7%
Q3 25
51.1%
-23.7%
Q2 25
-24.1%
-16.5%
Q1 25
80.4%
1.2%
Q4 24
-59.2%
-10.6%
Q3 24
57.1%
-32.6%
Q2 24
-38.3%
-35.2%
Q1 24
79.1%
-21.8%
Capex Intensity
EB
EB
TMCI
TMCI
Q4 25
0.0%
3.8%
Q3 25
0.0%
5.6%
Q2 25
0.0%
10.1%
Q1 25
0.1%
6.7%
Q4 24
0.0%
4.5%
Q3 24
0.2%
6.4%
Q2 24
0.1%
3.9%
Q1 24
0.4%
7.7%
Cash Conversion
EB
EB
TMCI
TMCI
Q4 25
Q3 25
5.76×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

TMCI
TMCI

Segment breakdown not available.

Related Comparisons